Council of the
European Union
Brussels, 11 January 2019
(OR. en)
5130/19
Interinstitutional File:
2018/0161(COD)
LIMITE
PI 2
CODEC 34
COMPET 16
PHARM 1
IA 3
NOTE
From:
Presidency
To:
Permanent Representatives Committee
No. prev. doc.:
15777/18, WK 194/2019
No. Cion doc.:
9485/18 + ADD1 + ADD2 + ADD3 + ADD 4
Subject:
Proposal for a Regulation amending Regulation (EC) No 469/2009
concerning the supplementary protection certificate for medical products
- Mandate for negotiations with the European Parliament
I.
INTRODUCTION
The Commission presented the above-mentioned proposal to the Council on 28 May 2018. The
proposed Regulation is one of the Commission's initiatives under the Single Market Strategy.
It aims at a targeted recalibration of certain aspects of Supplementary Protection Certificate (SPC)
protection by introducing an SPC manufacturing waiver for export purposes in order to remove the
competitive disadvantages EU-based manufacturers of generics and biosimilars are currently facing
vis-à-vis manufacturers established outside the EU. The waiver will enable EU-based manufacturers
of generics and biosimilars to produce them, provided their production is for export to non-EU
countries, while their originals are still protected by an SPC within the EU.
5130/19
BM/gb
1
ECOMP.3.B
LIMITE
EN
The proposal has been intensively discussed in the Intellectual Property Working Party between
June 2018 and 8 January 2019. Four revised texts have been prepared to find compromise solutions.
Substantial progress was achieved but there is still no complete agreement on the text.
The text set out in the Annex to this note reflects the outcome of this work. The Presidency has
taken into account the positions expressed by delegations and tried to reconcile them in order to
produce a balanced text that can be endorsed by COREPER. The text contained in the Annex
presents, in
bold underlined and strikethrough, the amendments to the text set out in 15777/18,
which was discussed at the Working Party meeting on 8 January 2019.
The remaining issues for discussion in COREPER, further addressed in point II. of this note, relate
to:
the scope of the waiver; and
the application in time.
In the EP the Committee report is scheduled to be voted in JURI meeting on 24 January 2019 and to
be approved during the plenary session in the following week. The Rapporteur Luis DE GRANDES
PASCUAL (EPP, ES) would thereby be granted a mandate to start negotiations with the Council on
this basis.
II. MAIN ELEMENTS OF THE PROPOSED COMPROMISE
Scope of the waiver: for export purposes
Discussions in the Working Party on the scope of the proposal focused on the question as to
whether the waiver should be extended to include not only the making for export to third countries,
but also the making for stockpiling purposes.
Introducing stockpiling would go beyond the scope of the Commission proposal. Strongly diverging
views have been expressed on this point, and as this is a political issue, this question has been
reserved for COREPER.
5130/19
BM/gb
2
ECOMP.3.B
LIMITE
EN
Delegations who support an extension of the waiver to stockpiling argued that this would further
improve the competitiveness of EU-based generics/biosimilars (namely faster entry into the EU
market as of day one after the expiry of the SPC) and by that would facilitate access to affordable
medicines for EU patients. Some of these delegations also called for the waiver to apply to intra-EU
exports (namely from ‘protected’ Member States to ‘unprotected’ ones) in addition to third
countries.
Other delegations were strongly opposed to such an extension of the waiver, arguing that this would
undermine the protection of SPC right holders in the EU and the interest of the originator industry
and consequently their investment in research and development of innovative medicines in the EU.
Moreover, the concern was raised that stockpiling would increase the risk of illicit diversion of
generics/biosimilars to the EU market.
The Presidency compromise text set out in the Annex aims at a balanced approach. Taking into
account the different positions, it therefore proposes the waiver to maintain the scope of the
Commission proposal and be limited to removing the possible competitive disadvantage
manufacturers of generics and biosimilars face when intending to do business
outside the EU. In
this context, the Presidency would like to recall that the production under the export waiver will
lead to an reinforcement of Union based supply chains of medicines, which can help a quick entry
of generics and biosimilars into the EU market after the expiry of the SPC(see new drafting in
recital (7)).
Application in time (Article 5(5))
The application in time was a key issue in the negotiations. Broad consensus was achieved in the
Working Party to provide for a two-phase approach, namely to apply the waiver
1)
up to a set date, only to SPCs that are
applied for on or after the entry into force of the
Regulation, and
2)
as of that date, to SPCs which have been
applied for before the entry into force of this
Regulation but which only
become effective after the entry into force of this Regulation.
5130/19
BM/gb
3
ECOMP.3.B
LIMITE
EN
The connecting factor for assessing whether the waiver applies under this concept thus is the date of
the filing of the application for the certificate.
However, no overall consensus was reached so far on the date as of which the second requirement
should kick in. The determination of that date, respectively the period that should elapse between
the entry into force of the Regulation and that date, was left to COREPER.
This period has to be set balancing the different interests involved: the need for legal certainty and
foreseeability for the SPC holders on the one side and the introduction of a waiver that is
economically interesting in view of the 'patent cliff" of the coming years on the other side (the term
"patent cliff" refers to the situation that, during a period starting from 2020 and ending in 2025,
patent protection will end for an exceptionally high number of economically important medical
drugs).
In the discussions in the Working Party, a number of delegations called for a period as short as
possible (two to three years) for the second requirement to apply after the entry into force of the
Regulation, whereas other delegations supported a period of five years, or even longer.
As a compromise between those positions, the Presidency proposes a period of 3,5 years after the
date of entry into force of the Regulation. Assuming an entry into force of the Regulation on
1 July 2019, the date as of which the above-mentioned second criterion would apply would thus be
1 January 2023
1.
In the view of the Presidency, this compromise would achieve a fair balance between the different
positions expressed. It would still leave a reasonable period of time to all stakeholders to adjust to
the new legal situation, while introducing the waiver in a manner that will be economically useful in
view of the 'patent cliff' of the coming years, since both the average-length of SPC coming into
effect after the entry into force of the Regulation (i.e. 3,5 years) and, by extension all full five-year
SPCs, will be subject, at some point in their lifetime (i.e. as of 1 January 2023), to being covered by
the exception. At the same time, this compromise will ensure that makers of generics and
biosimilars can benefit effectively, without excessive delay from the exception.
1 In the final Regulation this date would be adjusted to the date corresponding to 3,5 years after
the date of entry into force of the Regulation.
5130/19
BM/gb
4
ECOMP.3.B
LIMITE
EN
Notification obligation (information to be provided to the competent authorities and to the
SPC holder, and information to be published)
The Presidency compromise package on notification and information obligations seeks to meet the
requests of many delegations in favour of a regime as simple as possible that avoids unnecessary
additional burden for competent patent authorities.
The re-drafted notification requirement covers all information that certificate holders need for being
able to ensure and monitor compliance in relation to the rights conferred by their certificates, whilst
avoiding the disclosure of confidential or commercially sensitive information, such as the premises
of manufacture or details of future export intentions.
The information to be provided to the competent authority (the patent office) in the Member State
of making, and to the SPC holder in that Member State, is identical, and, in the interest of fair
competition and to avoid administrative burden for the competent authority having to handle this
information, all this information is to be published by that authority.
At the last Working Party meeting on 8 January 2019, some requests for further changes were made
regarding the elements of information to be notified/published (Article 5(3)). However, as these
requests were largely opposing each other and taking into account that the majority of delegations
did support the compromise concept as set out in document 15777/18, no further amendments to the
provisions on the notification obligation were introduced in the compromise text set out in the
Annex to this note.
5130/19
BM/gb
5
ECOMP.3.B
LIMITE
EN
III. CONCLUSION
The Permanent Representatives Committee is invited to examine and, subject to any possible
amendment that the Committee may consider necessary, endorse the text contained in the
Annex to this Note and to grant a mandate to the Presidency on the basis of that text to start
negotiations with the European Parliament with a view to reaching an agreement in first
reading.
5130/19
BM/gb
6
ECOMP.3.B
LIMITE
EN
ANNEX
Proposal for a
REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
amending Regulation (EC) No 469/2009 concerning the supplementary protection certificate for
medicinal products
(Text with EEA relevance)
THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,
Having regard to the Treaty on the Functioning of the European Union, and in particular Article 114
thereof,
Having regard to the proposal from the European Commission,
After transmission of the draft legislative act to the national parliaments,
Having regard to the opinion of the European Economic and Social Committee2,
Acting in accordance with the ordinary legislative procedure,
2 OJ C , , p. .
5130/19
BM/gb
7
ANNEX
ECOMP.3.B
LIMITE
EN
Whereas:
(1) Regulation (EC) No 469/2009 of the European Parliament and of the Council3 provides that
any product protected by a patent in the territory of a Member State and subject, prior to being
placed on the market as a medicinal product, to an administrative authorisation procedure as
laid down in Directive 2001/83/EC of the European Parliament and of the Council4 or
Directive 2001/82/EC of the European Parliament and of the Council5, may be the subject of a
supplementary protection certificate under the terms and conditions provided for in
Regulation (EC) No 469/2009.
(2) By providing for a period of supplementary protection of up to five years, Regulation (EC)
No 469/2009 seeks to promote, within the Union, the research and innovation that is
necessary to develop medicinal products, and to contribute to preventing the relocation of
pharmaceutical research outside the Union to countries that may offer greater protection.
(3) Since the adoption in 1992 of the predecessor to Regulation (EC) No 469/2009, markets have
evolved significantly and there has been huge growth in the manufacture of generics and
especially of biosimilars, in particular in countries outside the EU (‘third countries’) where
protection does not exist or has expired.
(4) The absence of any exception in Regulation (EC) No 469/2009 to the protection conferred by
a supplementary protection certificate has had the unintended consequence of preventing
makers of generics and biosimilars established in the Union from making in the Union, even
for the exclusive purpose of exporting to third country markets in which protection does not
exist or has expired. A further unintended consequence is that the protection conferred by the
certificate makes it more difficult for those makers to enter the Union market immediately
after expiry of the certificate, given that they are not in a position to build up production
capacity until the protection provided by the certificate has lapsed, by contrast with makers
located in third countries where protection does not exist or has expired.
3 Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009
concerning the supplementary protection certificate for medicinal products (OJ L 152, 16.6.2009,
p. 1).
4 Directive
2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the
Community code relating to medicinal products for human use (OJ L 311, 28.11.2001, p.
67).
5 Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the
Community code relating to veterinary medicinal products (OJ L 311, 28.11.2001, p. 1).
5130/19
BM/gb
8
ANNEX
ECOMP.3.B
LIMITE
EN
(5) This puts makers of generics and biosimilars established in the Union at a significant
competitive disadvantage compared with makers based in third countries that offer less or no
protection.
(6) Without any intervention, the viability of makers of generics and biosimilars established in
the Union could be under threat, with consequences for the Union’s pharmaceutical industrial
base as a whole.
(7) The aim of this Regulation is to promote the competitiveness of the Union, enhancing growth
and job creation in the internal market and contributing to a wider supply of products under
uniform conditions, by allowing makers of generics and biosimilars established in the Union
to make in the Union medicinal products or products for the exclusive purpose of export to
third country markets where protection does not exist or has expired, thus also helping these
makers to compete effectively in those third country markets. It should also complement the
efforts of the Union’s trade policy to ensure open markets for Union-based makers of
medicinal products or products. Over time, the Regulation should benefit the entire
pharmaceutical sector in the Union, by allowing all players, including newcomers, to reap the
benefits of the new opportunities opening up in the fast-changing global pharmaceutical
market. Furthermore, the common interest in the Union would be promoted, as
, through the
reinforcement of Union-based supply chains for medicines, medicines would become, to
some extent, more accessible to patients in the Union after the expiry of the certificate.
(8) In these specific and limited circumstances, and in order to create a level playing field
between Union-based makers and third country makers, it is appropriate to restrict the
protection conferred by a certificate so as to allow making for the exclusive purpose of export
to third countries and any related acts in the Union strictly necessary for making or for the
actual export itself, where such acts would otherwise require the consent of a certificate
holder (‘related acts’). For instance, such acts may include the possession, supply, import, or
making of products for the purpose of making a medicinal product containing that product, or
temporary storage of the product or advertising for the exclusive purpose of export to third
country destinations. The exception should also apply to related acts performed by third
parties who are in a contractual relationship with the maker.
5130/19
BM/gb
9
ANNEX
ECOMP.3.B
LIMITE
EN
(9) This exception should apply to a product, or a medicinal product containing that product,
protected by a certificate. It should cover the making of the product protected by a certificate
in the territory of a Member State and the making of the medicinal product containing that
product.
(10) The exception should not cover placing the product or medicinal product containing that
product, made for the exclusive purpose of export, on the market in the Member State where a
certificate is in force, either directly, or indirectly after export, nor should it cover re-
importation of the product to the market of a Member State in which a certificate is in force.
Moreover, it should not cover any act or activity for the purpose of import of products or
medicinal products into the Union merely for the purposes of repackaging and re-exporting. It
should not cover temporary storage of the product or medicinal product containing that
product for any purposes other than those set out in this Regulation.
(11) By limiting the scope of the exception to making for the purpose of export outside the Union
and acts strictly necessary for such making or for the actual export itself, the exception
introduced by this Regulation should not conflict with the normal exploitation of the product
or medicinal product containing that product in the Member State where the certificate is in
force, namely with the core exclusive right of the certificate holder to make that product for
the purpose of placing it on the Union market during the term of the certificate. In addition,
the exception should not unreasonably prejudice the legitimate interests of the certificate
holder, taking account of the legitimate interests of third parties.
(12) Safeguards should accompany the exception in order to increase transparency, to help the
holder of a certificate to enforce its protection in the Union and to reduce the risk of illicit
diversion onto the Union market during the term of the certificate.
5130/19
BM/gb
10
ANNEX
ECOMP.3.B
LIMITE
EN
(13) To this end, this Regulation should impose an information obligation on the maker, namely
the person established in the Union, on whose behalf the making of a product or medicinal
product containing that product for the exclusive purpose of export is done (this includes the
possibility of the person itself directly doing the making). Namely, the maker should provide
certain information to the authority which granted the certificate in the Member State where
the making is to take place. A common notification form should be provided for this purpose.
The information should be provided before the making starts for the first time in that Member
State, or before any related act prior to that making, whichever is the earlier. It should be
updated as and when appropriate. The making and related acts, including those performed in
Member States other than the one of making in cases where the product is protected by a
certificate in those other Member States too, should only fall within the scope of the exception
where the maker has sent this notification to the competent industrial property authority (or
other designated authority) of the Member State of making and has informed the holder of the
certificate granted in that Member State. Should making take place in more than one Member
State, a notification should be required in each of these Member States. In the interests of
transparency, the authority should be required to publish, as soon as possible, the information
it receives, together with the date of notification of that information. Member States should be
allowed to require that notifications, and updates to notifications, be subject to the payment of
a once-off fee. This fee should be set at a level which does not exceed the administrative cost
of processing notifications and updates.
5130/19
BM/gb
11
ANNEX
ECOMP.3.B
LIMITE
EN
(13a) The maker should also inform the certificate holder, through appropriate and documented
means, of the intention to make a product or medicinal product containing that product
pursuant to the exception, by providing the certificate holder with the same information as
notified to the authority. That information is limited to what is necessary and appropriate for
the certificate holder to assess whether the rights conferred by the certificate are being
respected, and does not include confidential or commercially sensitive information. The
information to the certificate holder may be provided by making use of the same common
notification form, and the information provided should be updated as and when appropriate.
(13b) Regarding related acts prior to the making, if any, the notification should list the name of the
Member State where the first related act, which would otherwise require the consent of a
certificate holder, is to take place, as this information is relevant to the timing of the
notification.
(13c) If the local marketing authorisation, or equivalent, in a specific third country, for a given
medicinal product, is published after the notification is made, the notifcation should be
promptly updated to include the reference number of that marketing authorisation, at the latest
before the actual export of the medicinal product to that third country takes place. If a
marketing authorisation or equivalent mechansim applies, but the reference number of the
granted authorisation is not published or is pending publication, the maker should be required
to provide, in the notification, either that reference number or the name of the third country of
export. As a failsafe, if no marketing authorisation or equivalent applies in that country, the
maker should then be required to provide, in the interests of transparency, the name of the
third country of export.
5130/19
BM/gb
12
ANNEX
ECOMP.3.B
LIMITE
EN
(13d) For reasons of proportionality, failure to comply with these requirements regarding a third
country would only affect exports to that country, and exports to such third country would
thus not benefit from the exception. It should be the responsibility of the maker established in
the Union to verify that protection does not exist or has expired in a country of export, subject
to any limitations or exemptions in that country. A notification to an authority and the
corresponding information to the certificate holder may be provided during the period
following
between the entry into force of the Regulation and the date on which the exception
itself becomes applicable.
(14) In addition, this Regulation should impose certain due diligence requirements on the maker as
a condition for the exception to operate. The maker should be required to inform persons
within its supply chain in the Union, including the exporter, through appropriate and
documented means, in particular contractual means, that the product or medicinal product
containing that product is covered by the exception introduced by this Regulation and is
intended for the exclusive purpose of export. A maker who failed to comply with these due
diligence requirements would not benefit from the exception, nor would any third party
performing a related act in the same or a different Member State where a certificate conferring
protection for the product was in force, and the holder of the relevant certificate would
therefore be entitled to enforce its rights under the certificate, while paying due regard to the
general obligation, set out in Directive 2004/48/EC of the European Parliament and of the
Council6, not to engage in abusive litigation.
(15) Furthermore, this Regulation should impose labelling requirements on the maker, in order to
facilitate, by means of a logo, identification of the product or medicinal product containing
that product as being exclusively intended for the purpose of export to third countries. The
making and related acts should only fall outside the protection conferred by a certificate if the
product or medicinal product containing that product is labelled in this manner. This labelling
obligation would be without prejudice to labelling requirements of third countries.
6 Directive 2004/48/EC of the European Parliament and of the Council of 29 April 2004 on the
enforcement of intellectual property rights (OJ L157, 30.4.2004, p. 45).
5130/19
BM/gb
13
ANNEX
ECOMP.3.B
LIMITE
EN
(16) Any act not covered by the exception introduced by this Regulation will remain within the
scope of the protection conferred by a certificate. Any illicit diversion onto the Union market,
during the term of the certificate, of any product or medicinal product containing that product
made within the terms of the exception, will remain prohibited.
(17) This Regulation is without prejudice to the respect of other intellectual property rights that
may protect other aspects of a medicinal product. This Regulation does not affect the
application of Union measures that aim to prevent infringements and facilitate enforcement of
intellectual property rights, including Directive 2004/48/EC and Regulation (EU) No
608/2013 of the European Parliament and of the Council7. Furthermore, this Regulation does
not affect the rules on the unique identifier provided for by Directive 2001/83/EC of the
European Parliament and of the Council and by Commission Delegated Regulation (EU)
2016/161. According to Directive 2001/83/EC, medicinal products produced exclusively for
export do not need to bear unique identifiers.
(18) This Regulation does not affect the application of Directives 2001/83/EC and 2001/82/EC, in
particular the requirements related to the manufacturing authorisation of medicinal products
manufactured for export. This includes compliance with the principles and guidelines of good
manufacturing practices for medicinal products and the use of active substances that have
been manufactured in accordance with good manufacturing practices for active substances
and distributed in accordance with good distribution practices for active substances.
7 Regulation (EU) No 608/2013 of the European Parliament and of the Council of 12 June 2013
concerning customs enforcement of intellectual property rights (OJ L 181, 29.6.2013, p. 15).
5130/19
BM/gb
14
ANNEX
ECOMP.3.B
LIMITE
EN
(19) To safeguard the rights of certificate holders, the exception should not apply to a certificate
that has already entered into effect at the date of entry into force of the Regulation. In order to
ensure that the rights of certificate holders are not excessively restricted, the exception
provided for in this Regulation should apply to certificates that are applied for on or after the
day of the entry into force of this Regulation. At the same time, in order to safeguard the aim
of this Regulation, and since a certificate enters into effect a relatively long time after its date
of filing, it is justified to bring within the scope of the Regulation, over a certain period of
time, a certificate that was applied for before the entry into force of this Regulation, but has
not yet entered into effect before that entry into force, and irrespective of whether or not that
certificate has been granted before the entry into force of the Regulation. Therefore, the
exception should apply, as from 1 January 2023, to a certificate that enters into effect as from
that entry into force. This ‘certain period of time’ for each individual certificate that enters
into effect after that entry into force should ensure that the exception is applied, on a
progressive basis, to such a certificate, depending on its date of entry into effect and its
duration. Such application of the exception would allow the holder of a granted certificate that
is not yet in effect by the date of the entry into force of the Regulation a reasonable period of
transition to adapt to the changed legal context, while at the same time ensuring that makers
of generics and biosimilars can benefit effectively, without excessive delay, from the
exception.
(19a) An applicant for a certificate might be expected to file an application at around the same date
in each Member State of filing. However due to differences in national procedures for
examination of applications, the date of grant might vary significantly from one Member State
to another, thereby creating disparities in the legal situation of the applicant in the different
Member States where the certificate is applied for. Introducing the exception on the basis of
the date of filing of the application for a certificate would therefore promote uniformity and
limit this risk of disparities.
5130/19
BM/gb
15
ANNEX
ECOMP.3.B
LIMITE
EN
(20) The Commission should carry out an evaluation of this Regulation. Pursuant to paragraph 22
of the Interinstitutional Agreement between the European Parliament, the Council of the
European Union and the European Commission on Better Law-Making of 13 April 20168,
that evaluation should be based on the five criteria of effectiveness, efficiency, relevance,
coherence and added value and should provide the basis for impact assessments of possible
further measures. The evaluation should take into account exports to outside the Union and
the ability of generics and especially biosimilars to enter markets in the Union as soon as
possible after a certificate lapses. In particular, this evaluation should review the effectiveness
of the exception in the light of the aim to restore a global level playing field for generic and
biosimilar firms in the Union and a swifter entry of generic and especially biosimilar
medicines onto the market after a certificate lapses. It should also study the impact of the
exception on research and production of innovative medicines in the Union by holders of
certificates and consider the balance between the different interests at stake, including those
of public health.
(21) It is necessary and appropriate for the achievement of the basic objective, of providing a level
playing field for makers of generic and biosimilar with their competitors in third country
markets where protection does not exist or has expired, to lay down rules restricting the
exclusive right of a certificate holder to make the product in question during the term of the
certificate, and also to impose certain information and labelling obligations on makers
wishing to take advantage of those rules
. This Regulation complies with the principle of
proportionality, and does not go beyond what is necessary in order to achieve the objectives
pursued, in accordance with Article 5(4) of the Treaty on European Union.
8 OJ L 123, 12.5.2016, p. 1.
5130/19
BM/gb
16
ANNEX
ECOMP.3.B
LIMITE
EN
(22) This Regulation respects fundamental rights and observes the principles recognised by the
Charter of Fundamental Rights of the European Union. In particular, this Regulation seeks to
ensure full respect for the right to property in Article 17 of the Charter by maintaining the
core rights of the certificate, by confining the exception provided for in this Regulation to the
making of a product or a medicinal product containing that product only for the purpose of
export outside the Union and to the acts strictly necessary for such making or for the actual
export itself. This exception does not go beyond what is necessary and appropriate in the light
of the overall objective of this Regulation, which is to promote the competitiveness of the
Union by avoiding delocalisations and allowing Union-based makers of generics and
biosimilars to compete on fast-growing, global markets where protection does not exist or has
already expired. Indeed, it is necessary to benefit from those positive economic effects arising
from the exception, as otherwise the Union would risk substantially weakening its position as
a hub for pharmaceutical development and manufacturing. It is therefore appropriate to
introduce that exception in order to increase the competitive position of Union-based makers
of generics and biosimilars in third countries whose markets are in any event open to
competition, whilst leaving the scope and duration of the protection granted by the certificate
in the Union untouched. The appropriateness of the measure is further ensured by providing
for appropriate safeguards regulating the use of the exception. The Regulation should allow
sufficient time for public authorities to put in place the necessary arrangements to receive and
publish notifications,
5130/19
BM/gb
17
ANNEX
ECOMP.3.B
LIMITE
EN
HAVE ADOPTED THIS REGULATION:
Article 1 – Amendment of Regulation (EC) No 469/2009
Regulation (EC) No 469/2009 is amended as follows:
(0) in Article 1, the following point is added:
‘(f) ‘maker’ means the person established in the Union on whose behalf the making of a
product or a medicinal product containing that product, for the exclusive purpose of
export to third countries, is done;’
(g) ‘a product, or a medicinal product containing that product’ means a product, or a
product to be placed on the market as a medicinal product, protected by a certificate.’;
(1) Article 5 is replaced by the following:
‘Article 5 – Effects of the certificate
1.
Subject to the provisions of Article 4, the certificate shall confer the same rights as conferred
by the basic patent and shall be subject to the same limitations and the same obligations.
2.
By way of derogation from paragraph 1, the certificate referred to in paragraph 1 shall not
confer protection against a particular act which would otherwise require the consent of the
holder of the certificate referred to in Article 11 (‘the certificate holder’) if the following
conditions are met:
(a) the act comprises:
(i)
making a product or a medicinal product containing that product, for the
exclusive purpose of export to third countries; or
(ii) any related act that is strictly necessary for that making in the Union or for
the actual export itself;
(b) the maker, through appropriate and documented means, notifies the authority
referred to in Article 9(1) of the Member State where that making is to take place
and informs the certificate holder of the information listed in paragraph 3 no later
than three months before the start date of making in that Member State, or no later
than three months before the first related act prior to that making that would
5130/19
BM/gb
18
ANNEX
ECOMP.3.B
LIMITE
EN
otherwise be prohibited by the protection conferred by a certificate, whichever is
the earlier;
(ba) if the information listed in paragraph 3 changes, the maker shall notify the
authority referred to in Article 9(1) and shall inform the certificate holder, before
these changes take effect;
(c) the maker ensures that a logo, in the form set out in Annex -II, is affixed to the
outer packaging of the product or
of the product to be placed on the market as a
medicinal product
containing that product, referred to in paragraph 2(a)(i), and,
where feasible, to its immediate packaging;
(d) the maker complies with the requirements of paragraph 4 and, if applicable, of
Article 12(2).
3.
The information for the purposes of paragraph 2(b) shall be as follows:
(a) the name and address of the maker;
(b) the Member State where the making is to take place and the Member State where
the
first
related act prior to that making is to take place;
(c) the number of the certificate granted in the Member State of making, and the
number of the certificate granted in the Member State of the
first
related act prior
to that making;
(d) (deleted)
(e) (deleted)
(f)
for medicinal products, the reference number of the marketing authorisation or
equivalent in each third country of export or, failing that, the name of that third
country.
3a. Annex -I includes a standard form that shall be used by makers for notifications to authorities
under paragraph 2(b).
5130/19
BM/gb
19
ANNEX
ECOMP.3.B
LIMITE
EN
3b. Failure to comply with the requirements of paragraph 3(f) in respect of a third country shall
only affect exports to that country, and such exports would thus not benefit from the
exception.
4.
The maker shall ensure, through appropriate and documented means, that
any persons in a
contractual relationship with the maker who performs acts falling within paragraph 2(a)(ii) are
is fully informed and aware of the following:
(a) that those acts are subject to the provisions of paragraph 2;
(b) that the placing on the market, import or re-import of the product referred to in
paragraph 2(a)(i) might infringe the certificate referred to in paragraph 2 where,
and as long as, that certificate applies.
5.
Paragraph 2 shall apply to certificates that are applied for on or after the entry into force of
this Regulation.
From 1 January 20239, paragraph 2 shall also apply to certificates that have been applied for
before the entry into force of this Regulation and that enter into effect on or after the entry
into force of this Regulation.
Paragraph 2 shall not apply to certificates that enter into effect before the entry into force of
this Regulation.’;
(2) in Article 11, the following paragraph is added:
4.
‘The authority referred to in Article 9(1) shall publish, as soon as possible, the information
listed in Article 5(3), together with the date of notification of that information. It shall also
publish, as soon as possible, any changes to this information notified in accordance with
Article 5(2)(ba).’;
9
Date to be replaced by the actual date of entry into force of the Regulation, plus 3,5 years.
5130/19
BM/gb
20
ANNEX
ECOMP.3.B
LIMITE
EN
(3) Article 12 is replaced by the following:
‘Article 12 –
Fees
1.
Member States may require that the certificate be subject to the payment of annual fees.
2.
Member States may require that the notifications referred to in Article 5(2)(b) and (ba) be
subject to the payment of a fee.’;
(4) the following Article is inserted:
‘Article 21a – Evaluation
No later than five years after the date referred to in Article 5(5), and every five years thereafter,
the Commission shall carry out an evaluation of Articles 5(2) to (4) and 11 and present a report
on the main findings to the European Parliament, the Council and the European Economic and
Social Committee.’;
(5) the Annexes to this Regulation are inserted as Annex –II and –I.
Article 2 – Entry into force
This Regulation shall enter into force on the twentieth day following that of its publication in the
Official Journal of the European Union.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels,
For the European Parliament
For the Council
The President
The President
5130/19
BM/gb
21
ANNEX
ECOMP.3.B
LIMITE
EN
ANNEX -II
Logo
This logo should appear in black colour and of such size as to be sufficiently visible.
5130/19
BM/gb
22
ANNEX
ECOMP.3.B
LIMITE
EN
ANNEX -I
Form for notification pursuant to Article 5(2)(b)
Tick the appropriate box
New notification
Update of an existing notification
(a) Name and address of the maker
…
(b) Member State where making is to take place and
Member State of
…
Member State where first
related act
(if any) prior to
making:
making is to take place
(Member State of
first related act
(if
…
any))
(c) Number of certificate granted in the Member
Certificate of
State of making and number of certificate granted in
Member State of
…
Member State of first
related act
(if any) prior to
making
making
(Certificate of
Member State of
…
first related act
(if
any))
(d)*
(deleted)
(e)*
(deleted)
(f) for medicinal products, reference number of
…
marketing authorisation or equivalent in each third
country of export, or name of third country of export
…
…
*points (d) and (e) of Article 5(3) have been deleted; however, for ease of reference in the neogotiations, the
numbering of paragraphs, both in the form above and in Article 5, is retained, but will be adjusted before
adoption of the Regulation. In addition, the current points (a) to (f) will be re-numbered at the jurists-linguists
stage (i.e. meaning that current point (f) will become point (d)). These changes will also be carried through in
Article.
5130/19
BM/gb
23
ANNEX
ECOMP.3.B
LIMITE
EN
